FARN Faron Pharmaceuticals Oy

LSE · GB · Healthcare · Biotechnology · faron.com

36.50GBp0.00%Mkt Cap: 80.49M $P/E: —Today

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap80.49M USD

Enterprise Value65.21M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-29.63M USD

Revenue/Share0.01 GBp

Last Price36.50 GBp

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees36

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-4.77

PEG—

EV/EBITDA-3.12

EV/Revenue—

P/S—

P/B7.44

EPS (TTM)-0.10

EPS (Forward)-0.08

52W Range

34.001% of range210.00

52W High210.00 GBp

52W Low34.00 GBp

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE147.28%

ROA-158.73%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-19.48M USD

CapEx (TTM)241.30K USD

FCF Margin—

FCF Yield-16.48%

Net Debt-15.28M USD

Net Debt/EBITDA0.73

Balance Sheet

Debt/Equity-1.33

Current Ratio2.40

Quick Ratio2.28

Book Value/Sh0.05 GBp

Cash/Share0.16 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)990.64 GBp

Upside (mean)+2614.1%

Target Range990.64 GBp – 990.64 GBp

# Analysts1

Ownership

Shares Out.202.88M

Float136.59M

Insiders16.17%

Institutions21.05%

Technical

SMA 5038.57 (-5.4%)

SMA 20063.74 (-42.7%)

Beta1.12

S&P 52W Chg14.58%

Avg Vol (30d)46.45K

Avg Vol (10d)47.12K

Technical Indicators

RSI (14)47.2

MACD-0.5557

MACD Signal-0.9122

MACD Hist.+0.3564

BB Upper38.58 GBp

BB Middle35.91 GBp

BB Lower33.24 GBp

BB Width14.85%

ATR (14)2.859 GBp

Vol Ratio (20d)0.79x